INO Financial Facts

License fee and milestone revenue from affiliated entity: 574.6K
Loss from operations: -20.2M
See Full Income Statement

Cash and cash equivalents: 23.25M
Accumulated deficit: -408.6M
See Full Balance Sheet

Inovio Pharma (INO) Earnings

  |   Expand Research on INO
Next EPS Date 3/14/17 *Est. EPS Growth Rate -500.0% *Last Qtr.
Average EPS % Beat Rate -8.8% Revenue Growth Rate -48.1% *Last Qtr.
Average % Move 1-Wk after EPS +5.3% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/9/16 Q316 -$0.28-$0.26 -$0.02$12.54M$5.16M N/A Details
8/8/16 Q216 -$0.26-$0.21 -$0.05$6.2M$4.95M N/A Details
5/9/16 Q116 -$0.11-$0.14 +$0.03$8.1M$4.75M N/A Details
3/14/16 Q415 -$0.25-$0.20 -$0.05$5.94M$6.96M N/A Details
11/9/15 Q315 $0.07N/A N/A $24.18M$1.84M N/A Details
8/10/15 Q215 -$0.09-$0.13 +$0.04$5.3M$5.52M N/A Details
5/11/15 Q115 -$0.17-$0.11 -$0.06$5.2M$7.04M N/A Details
3/16/15 Q414 -$0.12-$0.10 -$0.02$2.5M$5.24M N/A Details